translation agency

NLM AIDSLINE
[Prevalence of antibodies against LAV/HTLV-III in patients with terminal renal insufficiency treated with hemodialysis and following renal transplantation]
Fassbinder W; Kuhnl P; Neumayer HH; Offermann G; Seidl S; Schoeppe W
November 30, 1986
Dtsch Med Wochenschr. 1986 Jul 11;111(28-29):1087-90. Unique Identifier

Sera of 1046 patients undergoing haemodialysis for terminal renal failure or after renal transplantation were tested with the ELISA screening test for anti-LAV/HTLV-III and, if positive, the Western blot and ELAVIA tests. Four patients (0,38%) had true antibodies against LAV/HTLV-III, confirmed by the Western blot and ELAVIA tests. These patients had definite signs of cellular immune defects. They had received transplants from drug addict donors. Such kidneys should therefore no longer be used for transplantation. In addition, 29 patients (2.8%) had false-positive antibodies against LAV/HTLV-III in the ELISA test, unconfirmed in the Western blot and ELAVIA tests. The false-positive result was presumably due to cross-reaction with HLA antibodies. Sera of dialysis and transplantation patients who had received many blood transfusions should therefore be especially carefully tested before a diagnosis of infection with LAV/HTLV-III is made.

Antibodies, Viral/*ANALYSIS English Abstract Enzyme-Linked Immunosorbent Assay *Hemodialysis Human HTLV-BLV Viruses/*IMMUNOLOGY Kidney/*TRANSPLANTATION Kidney Failure, Chronic/*IMMUNOLOGY/SURGERY/THERAPY *Kidney Transplantation JOURNAL ARTICLE

www.aegis.org